CN107260741A - 一种用于家蚕真菌病防治的伏立康唑溶液片及制备方法 - Google Patents
一种用于家蚕真菌病防治的伏立康唑溶液片及制备方法 Download PDFInfo
- Publication number
- CN107260741A CN107260741A CN201610220306.7A CN201610220306A CN107260741A CN 107260741 A CN107260741 A CN 107260741A CN 201610220306 A CN201610220306 A CN 201610220306A CN 107260741 A CN107260741 A CN 107260741A
- Authority
- CN
- China
- Prior art keywords
- voriconazole
- silkworm
- solution piece
- piece according
- lactose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000255789 Bombyx mori Species 0.000 title claims abstract description 37
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 title claims abstract description 29
- 229960004740 voriconazole Drugs 0.000 title claims abstract description 29
- 208000031888 Mycoses Diseases 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title abstract description 6
- 239000000843 powder Substances 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 7
- 230000008569 process Effects 0.000 claims abstract description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 13
- 239000008101 lactose Substances 0.000 claims description 13
- 235000008708 Morus alba Nutrition 0.000 claims description 9
- 240000000249 Morus alba Species 0.000 claims description 9
- 238000004659 sterilization and disinfection Methods 0.000 claims description 7
- 238000009366 sericulture Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 abstract description 5
- 206010017533 Fungal infection Diseases 0.000 abstract description 3
- 208000024386 fungal infectious disease Diseases 0.000 abstract 2
- 230000000384 rearing effect Effects 0.000 description 6
- 241000233866 Fungi Species 0.000 description 5
- 229930040373 Paraformaldehyde Natural products 0.000 description 5
- 229920002866 paraformaldehyde Polymers 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 241000228212 Aspergillus Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 2
- 235000019738 Limestone Nutrition 0.000 description 2
- 235000011941 Tilia x europaea Nutrition 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 238000009360 aquaculture Methods 0.000 description 2
- 244000144974 aquaculture Species 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000004571 lime Substances 0.000 description 2
- 239000006028 limestone Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000008686 ergosterol biosynthesis Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Farming Of Fish And Shellfish (AREA)
- Fodder In General (AREA)
Abstract
本发明公开了一种用于家蚕真菌病防治的伏立康唑溶液片及制备方法,所述散剂用于家蚕真菌病的防治。该溶液片包含如下成分:伏立康唑、赋型剂。同时本发明还公开了该溶液片的制备方法及其应用方法。本发明工艺简单、成本低廉、使用方便,可应用于家蚕真菌病的防治。
Description
技术领域
本发明公开了一种用于家蚕真菌病防治的伏立康唑溶液片及制备方法,涉及到农业领域,属于兽药类的蚕药序列。
背景技术
桑蚕起源于中国,桑蚕养殖业是我国传统的农副业,是农民增收的重要途径之一。但蚕在密集群体饲养条件下极易受病原微生物、寄生虫或其他外界因素的影响而引起各种疾病。蚕病危及蚕茧产量和质量,一旦扩散蔓延,还会导致整个蚕业经营失败。真菌病是家蚕传染性疾病中主要病害之一,前期蚕种、病蚕的尸体、粪便、体液以及被病蚕污染的蚕室、蚕具、桑叶等均可能成为传染源。目前,生产实践上主要通过使用石灰粉、多聚甲醛粉等对蚕体进行消毒、干燥蚕座,从而达到预防真菌病发生的目的。虽有成效,然而石灰粉、多聚甲醛抗真菌效力有限,对劳动者劳动防护要求高(有皮肤粘膜、刺激性),生产实践中迫切需要开发出安全、有效、便于使用的新产品。
伏立康唑是一种三唑类广谱抗真菌药物,用于人类真菌感染病的治疗已近13年,其广谱高效及临床安全性已得到充分临床验证,其作用机制是抑制真菌中由细胞色素P450介导的14α-甾醇去甲基化,从而抑制麦角甾醇的生物合成,影响细胞膜通透性,抑制真菌生长、导致其死亡。目前抗真菌药物尚未见应用于桑蚕养殖业,体外试验表明伏立康唑具有广谱抗真菌作用,无需进行体内代谢即可产生药效,因此适用于蚕种、桑叶、养殖器具、养殖场所的灭菌,因此将其制备为便于使用的溶液片,配制方便,便于使用。因其高效,本品单剂量主药用量少,因此本品成本低廉,经济上具有推广价值。
发明内容
本发明公开了一种伏立康唑溶液片用于家蚕真菌病的防治。
首先,本发明所述的伏立康唑溶液片,其特征在于由伏立康唑、可溶性乳糖构成。
进一步,本发明所述的伏立康唑溶液片的各成分含量为:
伏立康唑 1.0-10.0%
可溶性乳糖 90.0-99.0%
其次,本发明还提供了一种伏立康唑溶液片的制备方法。这部分发明是由以下方案实现的:
(1)所用原辅料配比为:
伏立康唑 10-100份
可溶性乳糖 900-990份
并通过如下步骤制成:
(a)过筛:将各原辅料过150目筛,备用。
(b)混合:将称量好的伏立康唑加入等量的可溶性乳糖混匀后,再加入已有物料重量的可溶性乳糖,混匀;重复上述过程,直至物料完全混匀(等量递增法以保证物料混合均匀)。
(c)压片:取上述粉末,采用压片机直接压片,调节片重为1±0.01g;
(d)包装:将压制好的片剂以适当容器分装(如塑料瓶),密闭。
本发明所制的伏立康唑溶液片用于防治家蚕真菌病,其实施应用方法为:取本品,溶于适量冷开水中(每片约5L),以喷雾器进行均匀喷洒。适用于:1)养蚕器具、场所的消毒;2)桑叶消毒(桑叶晾干后,方可饲喂)。
本发明具有如下有益效果,与目前生产实践中普遍使用的生石灰粉、多聚甲醛粉相比,其对家蚕真菌病的防治效果更佳,且避免了生石灰粉、多聚甲醛粉对人体的刺激性和对环境的污染,使用方便。
具体实施例
以下通过数个具体实施例来进一步说明本发明。应当理解:下列的实施例并非是对本发明的进一步限定,本领域技术人员在充分理解本发明的基础上对实施例进行的调整,也在本发明的保护范围之内。
实施例1
所用原辅料配比为:
伏立康唑 10g
可溶性乳糖 990g
以上原辅料制成1kg。
实施例2
所用原辅料配比为
伏立康唑 50g
可溶性乳糖 950g
以上原辅料制成1kg。
实施例3
所用原辅料配比为
伏立康唑 100g
可溶性乳糖 900g
以上原辅料制成1kg。
对比实施例1
以市售多聚甲醛粉(大蚕用)进行对比试验。
对比实施例2
以可溶性乳糖进行对比试验。
实施例4
防治效果考察。挑取白僵菌、绿僵菌、曲霉菌分生孢子,置于液体培养基中,摇床26℃,150转/分,4天后,液体培养基呈混浊状,停止培养作为母液。
蚕饲养至5龄,将蚕移出,以药棉蘸取白僵菌、绿僵菌、曲霉菌分生孢子悬浊液,涂抹于蚕座、桑叶,模拟感染环境。将实施例1-3及各对比实施例,分别立即进行蚕座、桑叶消毒给药,将蚕移回。饲养7天,考察发病率,每组设三个平行组。结果见下表。
实施例5
对家蚕生长及茧质的影响。取三龄起蚕,每日以实施例1-3分别给药对蚕座、桑叶消毒1次,另设空白对照组相同饲养。饲养至上簇。调查生长发育、病情、分析产量、茧质、丝质。产量结果见下表:
项目 | 实施例1组 | 实施例2组 | 实施例3组 | 对照组 |
试验头数 | 1000 | 1000 | 1000 | 1000 |
上茧粒数 | 952 | 962 | 965 | 911 |
鲜茧重量(克) | 1811 | 1848 | 1841 | 1735 |
单粒茧重(克) | 1.902 | 1.921 | 1.908 | 1.905 |
对上茧进行仪检,结果见下表:
项目 | 实施例1组 | 实施例2组 | 实施例3组 | 对照组 |
100克茧粒数 | 60 | 59 | 61 | 60 |
茧层重(g) | 10.5 | 10.6 | 10.8 | 10.6 |
干壳量(g) | 9.2 | 9.3 | 9.4 | 9.3 |
经试缫,丝质情况见下表:
从上述实施例可见,本发明技术方法可行,对家蚕真菌病的防治效果良好,完全可以满足生产上防治家蚕真菌病的需要,操作者无特殊劳动防护,对人体无不良刺激。对家蚕安全,对家蚕的生长发育、蚕茧产量、蚕茧质量、蚕丝质量无不良影响。
Claims (7)
1.一种用于真菌病防治的伏立康唑溶液片,其特征在于由伏立康唑、赋型剂组成。
2.根据权利要求1所述的伏立康唑溶液片,其特征在于所述片剂为溶液片;所述赋型剂为乳糖。
3.根据权利要求1所述的伏立康唑溶液片,所述乳糖为可溶性乳糖。
4.根据权利要求1所述的伏立康唑溶液片,其特征在于包含以下组分(按重量计):伏立康唑1.0-10%,赋型剂为为90.0-99.0%。
5.根据权利要求1所述的伏立康唑溶液片,其特征在于伏立康唑及乳糖均粉碎至150目筛以下。
6.根据权利要求1所述的伏立康唑溶液片,其特征在于用于家蚕真菌病防治。
7.根据权利要求1所述的伏立康唑溶液片,其应用方法为:取本品,溶于适量冷开水中(每片约5L),以喷雾器进行均匀喷洒。适用于:1)养蚕器具、场所的消毒;2)桑叶消毒(桑叶晾干后,方可饲喂)。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610220306.7A CN107260741A (zh) | 2016-04-06 | 2016-04-06 | 一种用于家蚕真菌病防治的伏立康唑溶液片及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610220306.7A CN107260741A (zh) | 2016-04-06 | 2016-04-06 | 一种用于家蚕真菌病防治的伏立康唑溶液片及制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107260741A true CN107260741A (zh) | 2017-10-20 |
Family
ID=60052132
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610220306.7A Pending CN107260741A (zh) | 2016-04-06 | 2016-04-06 | 一种用于家蚕真菌病防治的伏立康唑溶液片及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107260741A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050043251A1 (en) * | 2003-08-20 | 2005-02-24 | Fairfield Clinical Trials, Llc | Method of treatment of otitis externa |
CN108938576A (zh) * | 2017-05-25 | 2018-12-07 | 万特制药(海南)有限公司 | 一种伏立康唑分散片及其制备方法 |
-
2016
- 2016-04-06 CN CN201610220306.7A patent/CN107260741A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050043251A1 (en) * | 2003-08-20 | 2005-02-24 | Fairfield Clinical Trials, Llc | Method of treatment of otitis externa |
CN108938576A (zh) * | 2017-05-25 | 2018-12-07 | 万特制药(海南)有限公司 | 一种伏立康唑分散片及其制备方法 |
Non-Patent Citations (2)
Title |
---|
MANJUSHA M.ETL: "Voriconazole suppresses the growth of Leishmania species", 《PARASITOL RES》 * |
张树坤 等: "稻纵卷叶螟人工饲料中防霉剂对曲霉的抑制效果", 《南京农业大学学报》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6535419B2 (ja) | コウモリ蛾の幼虫の人工飼料及びその調製方法 | |
CN111011313B (zh) | 一种提高赤眼蜂后代雌性比例的方法及其应用 | |
CN103005144B (zh) | 一种中药微生物发酵制剂及其制备方法 | |
CN1317566A (zh) | 菌草栽培灵芝的技术 | |
CN106305610A (zh) | 一种哺乳期母猪的养殖方法 | |
CN106563129B (zh) | 一种用于伤口防护的组合物及其形成的敷贴 | |
CN107889942A (zh) | 微生物发酵饲料及其制备方法 | |
CN113967243B (zh) | 一种用于防治家禽腹泻的发酵中药制剂及其制备方法 | |
CN107260741A (zh) | 一种用于家蚕真菌病防治的伏立康唑溶液片及制备方法 | |
CN112755130B (zh) | 防控家蚕白僵病的组合物及其制备和应用 | |
CN1089000C (zh) | 一种治疗鸡病的兽药 | |
CN101708187A (zh) | 一种用于防治水产动物水霉病的干粉制剂及其制备方法 | |
CN107137528A (zh) | 防治海马烂尾病的药物及组合物 | |
Manimuthu et al. | Influence of herbal tonic Alloe on the overall performance of the mulberry silkworm, Bombyx mori L. | |
RU2431491C1 (ru) | Способ получения препарата натуральных половых феромонов хряка | |
CN1327047A (zh) | 一种用蚕蛹培养拟青霉菌的方法及药用用途 | |
CN110800693B (zh) | 一种无抗鸡蛋的生产方法 | |
CN115720898B (zh) | 一种家蚕养殖用消毒剂及其制备和应用方法 | |
CN113367099B (zh) | 一种无球虫实验鸽的培育方法和应用 | |
CN103301242B (zh) | 一种中草药组合物在制备防治草鱼虫菌并发综合症复方制剂中的用途 | |
CN1164278C (zh) | 一种用于治疗烧伤的生物制剂及其制备方法 | |
CN106577524A (zh) | 一种预防钩虫病的养猪方法 | |
CN106983771B (zh) | 防治海马头部溃烂病的药物及组合物 | |
Priya et al. | Treatment Using Medicinal Plants in Fish and Shrimp | |
US20210023154A1 (en) | Biological microbial drug for treating skin diseases, and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Yang Dalong Inventor after: Ding Yimei Inventor after: Kong Rong Inventor before: Yang Dalong Inventor before: Ding Yimei |
|
CB03 | Change of inventor or designer information | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171020 |
|
RJ01 | Rejection of invention patent application after publication |